Traveler's Diarrhea Market - 2024-2031
The Traveler's Diarrhea Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Traveler's Diarrhea Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By using OTC products coupled with antibiotic resistance
By Drug Class
Both primary and secondary data sources have been used in the global Traveler's Diarrhea Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
A Traveler's Diarrhea Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By using OTC products coupled with antibiotic resistance
By Drug Class
- Antibiotics*
- Azithromycin,
- Ciprofloxacin
- Quinolones
- Rifaximi
- Oral Rehydration Therapy (ORS),
- Antidiarrheal Agents
- Vaccines/Prophylactics
- Others
- Bacteria*
- E. Coli
- Salmonella Spp
- Others
- Viruses
- Protozoa
- Adults*
- Children
- Retail Pharmacies*
- Hospital Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Traveler's Diarrhea Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Pathogen
3.3. Market Snippet by Age group
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Surge in the number of travelers
4.1.1.2. Growing awareness among travelers
4.1.2. Restraints:
4.1.2.1. Growing self-medication by using OTC products coupled with antibiotic resistance
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. PEST Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG CLASS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antibiotics*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.2.3. Azithromycin,
7.2.4. Ciprofloxacin
7.2.5. Quinolones
7.2.6. Rifaximi
7.3. Oral Rehydration Therapy (ORS),
7.4. Antidiarrheal Agents
7.5. Vaccines/Prophylactics
7.6. Others
8. BY PATHOGEN
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Segment
8.1.2. Market Attractiveness Index, By Pathogen Segment
8.2. Bacteria*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.2.3. E. Coli
8.2.4. Salmonella Spp
8.2.5. Others
8.3. Viruses
8.4. Protozoa
9. BY AGE GROUP
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
9.1.2. Market Attractiveness Index, By Age Group Segment
9.2. Adults*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Children
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Retail Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Hospital Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch
12.5. Company with disruptive technology
12.6. Start Up Companies
13. COMPANY PROFILES
13.1. Bausch Health Companies Inc (Salix Pharmaceuticals) *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Bristol-Myers Squibb Company
13.3. Cosmo Pharmaceuticals NV
13.4. Immuron Limited
13.5. Johnson & Johnson
13.6. Pfizer Inc
13.7. Procter & Gamble
13.8. Sanofi SA
13.9. Valneva Canada Inc
13.10. Sun Pharmaceutical Industries Ltd
13.11. Shanghai Yingrui Biopharma Co., Ltd
13.12. Shijiazhuang Gantuo Biotechnology Co., Ltd
13.13. PI & PI BIOTECH INC(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Pathogen
3.3. Market Snippet by Age group
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Surge in the number of travelers
4.1.1.2. Growing awareness among travelers
4.1.2. Restraints:
4.1.2.1. Growing self-medication by using OTC products coupled with antibiotic resistance
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. PEST Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG CLASS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antibiotics*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.2.3. Azithromycin,
7.2.4. Ciprofloxacin
7.2.5. Quinolones
7.2.6. Rifaximi
7.3. Oral Rehydration Therapy (ORS),
7.4. Antidiarrheal Agents
7.5. Vaccines/Prophylactics
7.6. Others
8. BY PATHOGEN
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Segment
8.1.2. Market Attractiveness Index, By Pathogen Segment
8.2. Bacteria*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.2.3. E. Coli
8.2.4. Salmonella Spp
8.2.5. Others
8.3. Viruses
8.4. Protozoa
9. BY AGE GROUP
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group Segment
9.1.2. Market Attractiveness Index, By Age Group Segment
9.2. Adults*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Children
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Retail Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Hospital Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug-Class
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch
12.5. Company with disruptive technology
12.6. Start Up Companies
13. COMPANY PROFILES
13.1. Bausch Health Companies Inc (Salix Pharmaceuticals) *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Bristol-Myers Squibb Company
13.3. Cosmo Pharmaceuticals NV
13.4. Immuron Limited
13.5. Johnson & Johnson
13.6. Pfizer Inc
13.7. Procter & Gamble
13.8. Sanofi SA
13.9. Valneva Canada Inc
13.10. Sun Pharmaceutical Industries Ltd
13.11. Shanghai Yingrui Biopharma Co., Ltd
13.12. Shijiazhuang Gantuo Biotechnology Co., Ltd
13.13. PI & PI BIOTECH INC(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us
